Medications mostly associated with priapism events : assessment of the 2015-2020 Food and Drug Administration (FDA) pharmacovigilance database entries
© 2022. The Author(s), under exclusive licence to Springer Nature Limited..
A range of drugs have a direct role in triggering ischaemic priapism. We aimed at identifying: a) which medications are associated with most priapism-reports; and, b) within these medications, comparing their potential to elicit priapism through a disproportionality analysis. The FDA Adverse Event Reporting System (FAERS) database was queried to identify those drugs associated the most with priapism reports over the last 5 years. Only those drugs being associated with a minimum of 30 priapism reports were considered. The Proportional Reporting Ratios (PRRs), and their 95% confidence intervals were computed. Out of the whole 2015-2020 database, 1233 priapism reports were identified, 933 of which (75.7%) were associated with 11 medications with a minimum of 30 priapism-reports each. Trazodone, olanzapine and tadalafil showed levels of disproportionate reporting, with a PRR of 9.04 (CI95%: 7.73-10.58), 1.55 (CI95%: 1.27-1.89), and 1.42 (CI95%: 1.10-1.43), respectively. Most (57.5%) of the reports associated with the phosphodiesterase type 5 inhibitors (PDE5Is) were related with concomitant priapism-eliciting drugs taken at the same time and/or inappropriate intake/excessive dosage. Patients taking trazodone and/or antipsychotics need to be aware of the priapism-risk; awareness among prescribers would help in reducing priapism-related detrimental sequelae; PDE5I-intake is not responsible for priapism by itself, when appropriate medical supervision is provided.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
International journal of impotence research - 36(2024), 1 vom: 19. Feb., Seite 50-54 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schifano, Nicolò [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 29.01.2024 Date Revised 04.02.2024 published: Print-Electronic CommentIn: Int J Impot Res. 2022 Mar 28;:. - PMID 35347301 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41443-022-00583-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341203734 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341203734 | ||
| 003 | DE-627 | ||
| 005 | 20240204231919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41443-022-00583-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1280.xml |
| 035 | |a (DE-627)NLM341203734 | ||
| 035 | |a (NLM)35597798 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schifano, Nicolò |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Medications mostly associated with priapism events |b assessment of the 2015-2020 Food and Drug Administration (FDA) pharmacovigilance database entries |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2024 | ||
| 500 | |a Date Revised 04.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Int J Impot Res. 2022 Mar 28;:. - PMID 35347301 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a A range of drugs have a direct role in triggering ischaemic priapism. We aimed at identifying: a) which medications are associated with most priapism-reports; and, b) within these medications, comparing their potential to elicit priapism through a disproportionality analysis. The FDA Adverse Event Reporting System (FAERS) database was queried to identify those drugs associated the most with priapism reports over the last 5 years. Only those drugs being associated with a minimum of 30 priapism reports were considered. The Proportional Reporting Ratios (PRRs), and their 95% confidence intervals were computed. Out of the whole 2015-2020 database, 1233 priapism reports were identified, 933 of which (75.7%) were associated with 11 medications with a minimum of 30 priapism-reports each. Trazodone, olanzapine and tadalafil showed levels of disproportionate reporting, with a PRR of 9.04 (CI95%: 7.73-10.58), 1.55 (CI95%: 1.27-1.89), and 1.42 (CI95%: 1.10-1.43), respectively. Most (57.5%) of the reports associated with the phosphodiesterase type 5 inhibitors (PDE5Is) were related with concomitant priapism-eliciting drugs taken at the same time and/or inappropriate intake/excessive dosage. Patients taking trazodone and/or antipsychotics need to be aware of the priapism-risk; awareness among prescribers would help in reducing priapism-related detrimental sequelae; PDE5I-intake is not responsible for priapism by itself, when appropriate medical supervision is provided | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Trazodone |2 NLM | |
| 650 | 7 | |a YBK48BXK30 |2 NLM | |
| 650 | 7 | |a Phosphodiesterase 5 Inhibitors |2 NLM | |
| 700 | 1 | |a Capogrosso, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Boeri, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Fallara, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Cakir, Omer Onur |e verfasserin |4 aut | |
| 700 | 1 | |a Castiglione, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Alnajjar, Hussain M |e verfasserin |4 aut | |
| 700 | 1 | |a Muneer, Asif |e verfasserin |4 aut | |
| 700 | 1 | |a Deho', Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Schifano, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Montorsi, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Salonia, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of impotence research |d 1992 |g 36(2024), 1 vom: 19. Feb., Seite 50-54 |w (DE-627)NLM074730967 |x 1476-5489 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2024 |g number:1 |g day:19 |g month:02 |g pages:50-54 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41443-022-00583-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2024 |e 1 |b 19 |c 02 |h 50-54 | ||